SCHEMBL10101383

SCHEMBL10101383

COc1cc(CCC(=O)O)cc2c1[C@]1(C)CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CS2(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CB P42338 1/20 0.39
ALOX15 P16050 2/20 0.35
ALOX12 P18054 2/20 0.35
PIK3CA P42336 2/20 0.34
PIK3CG P48736 2/20 0.34
FFAR1 O14842 1/20 0.34
CETP P11597 1/20 0.34
MAPKAPK2 P49137 1/20 0.33
PLA2G2A P14555 2/20 0.33
PTPN1 P18031 2/20 0.32
TRPM2 O94759 1/20 0.32
PTPN2 P17706 1/20 0.32
UGT2B7 P16662 2/20 0.32
TRPV1 Q8NER1 1/20 0.32
CDC25A P30304 1/20 0.31
DUSP3 P51452 1/20 0.31
SLC10A2 Q12908 1/20 0.31
NR1H4 Q96RI1 1/20 0.31
THRA P10827 1/20 0.30
THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10101391 0.88 PIK3CB (0.46) PIK3CBPIK3CAPIK3CGMAPKAPK2PTPN1
SCHEMBL10101385 0.86 KDM4E (0.40) PIK3CBALOX15ALOX12
SCHEMBL10101164 0.84 PIK3CB (0.45) PIK3CBALOX15ALOX12PIK3CAPIK3CG
SCHEMBL10101184 0.84 PIK3CB (0.39) PIK3CBALOX15ALOX12PIK3CAPIK3CG
SCHEMBL10101153 0.83 PIK3CB (0.42) PIK3CBALOX15ALOX12PIK3CAPIK3CG
SCHEMBL10101361 0.82 PIK3CB (0.40) PIK3CBALOX15ALOX12PIK3CAPIK3CG
SCHEMBL10101126 0.81 PIK3CB (0.39) PIK3CBALOX15ALOX12PIK3CAPIK3CG
SCHEMBL10101338 0.81 PIK3CB (0.41) PIK3CBALOX15ALOX12PIK3CAPIK3CG
SCHEMBL10101365 0.81 PIK3CB (0.39) PIK3CBALOX15ALOX12PIK3CAPIK3CG
SCHEMBL10101249 0.81 PIK3CB (0.40) PIK3CBALOX15ALOX12PIK3CAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101605-B2 SHIP1 modulators and methods related thereto AQUINOX PHARMACEUTICALS INC. (CA) 2012-01-24 US disclosed
US-20110136802-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS INC. (CA) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136802-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO PPM1D, PTPRO, PPM1G PIK3CB 98/4885ALOX15 2729/4885ALOX12 2762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.